

# Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

J. REQUENA,<sup>a</sup> A. B. ALVAREZ-PALOMO,<sup>a</sup> M. CODINA-PASCUAL,<sup>b</sup> R. DELGADO-MORALES,<sup>c,d†</sup> S. MORAN,<sup>c</sup> M. ESTELLER,<sup>c,e†</sup> M. SAL,<sup>a</sup> M. JUAN-OTERO,<sup>f</sup> A. BORONAT BARADO,<sup>f</sup> A. CONSIGLIO,<sup>g,h,i</sup> O. ADDELECCIA BOGLE,<sup>b</sup> E. WOLVERTANG,<sup>j</sup> D. OVCHINNIKOV,<sup>j</sup> I. ALVAREZ,<sup>k</sup> D. JARAQUEMADA,<sup>k</sup> J. MEZQUITA-PLA,<sup>a</sup> R. OLIVA,<sup>b,††</sup> M. J. EDEL<sup>ib</sup><sup>a,l</sup>

**Key Words.** Induced pluripotent stem cells • neural stem cells • immune response • Toll like receptor • TLR3 • cytokine • MHC I • HLA • inflammation

## ABSTRACT

When considering the clinical applications of autologous cell replacement therapy of human iPSC-derived cells there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC-derived cells including neural stem cells made from either retroviral, episomal or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC-derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC-NSC functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC-derived cells to viral infection. The sustained wild type TLR3 and TLR3 isoform over expression is central to understanding the altered immunogenicity of human iPSC-derived cells calling for screening of human iPSC-derived cells for TLR3 expression levels before applications. *STEM CELLS* ;9999:00–00

## SIGNIFICANCE STATEMENT

The cell reprogramming process alters the immune response of most iPSC-derived cells highlighting human TLR3 isoform over expression that functions to suppress innate immune signal transduction and provides an insight for future clinical applications of autologous human iPSC-derived cell transplantation. We propose that screening human iPSC clones and their derived cells for alterations in the genome of patient cells that include expression levels of human TLR3 and its shorter TLR3 isoform identified in this work is essential before embarking on “first in man” clinical trials or human disease modeling using human iPSC.

## INTRODUCTION

The discovery of methods to reprogram somatic human cells into tissue specific adult stem cells directly or by full reprogramming, to produce induced pluripotent stem cells (iPSC) has presented the possibility of an easy and abundant source of cells for autologous stem cell therapy to treat many human diseases [1–3]. Three major challenges that must be overcome before reprogrammed stem cells can

be used for clinical applications are genetic instability, proper differentiation to relevant cell types to regenerate damaged tissues and the immune response of transplanted cells. The interaction of the human immune system with autologous reprogrammed human cells remains an unexplored question.

It is well accepted that Toll receptors are a major part of the innate immune system essential for life [4]. Likewise, regulation of inflammation cytokines by toll-like receptor 3 (TLR3 -

<sup>a</sup>Molecular Genetics and Control of Pluripotency Laboratory, Department of Biomedicine, Faculty of Medicine, University of Barcelona, Casanova 143, Barcelona, Spain; <sup>b</sup>Genetics Unit, Department of Biomedicine, Faculty of Medicine, University of Barcelona, IDIBAPS and Hospital Clinic, Casanova 143, Barcelona, Spain; <sup>c</sup>Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain; <sup>d</sup>Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Maastricht University, Maastricht, The Netherlands. Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; <sup>e</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; <sup>f</sup>Hospital Clinic, Department of Clinical Immunology, Biomedical Diagnostic Center (CDB) Villarroel, 170, Barcelona; <sup>g</sup>Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; <sup>h</sup>Bellvitge University Hospital-IDIBELL, Department of Pathology and Experimental Therapeutics, University of Barcelona, Hospitalet de Llobregat, Spain; <sup>i</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; <sup>j</sup>Stem Cell Engineering Group, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, QLD, Australia; <sup>k</sup>Immunology Unit, Department of Cell Biology, Physiology and Immunology and Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, Bellaterra, Spain; <sup>l</sup>Department of Physiology, Anatomy and Genetics, Visiting Scholar, Oxford University

Correspondence: Michael J. Edel, University of Barcelona, Faculty of Medicine. 143 Casanova, 08036. Tel: 0034 934024518, e-mail: edel.michael@gmail.com. University of Western Australia, Harry Perkins Research Institute, School of Medicine and Pharmacology, Centre for Cell Therapy and Regenerative Medicine (CCTRM), Nedlands, 6009, WA, Australia.

<sup>†</sup>For comments on the methylome array: rdelgado@idibell.cat

<sup>††</sup>For comments on the proteomic screen: R. Oliva: roliva@ub.edu.

**One Sentence Summary:** Immune response of human iPSC-derived cells.

Received September 20, 2018; accepted for publication December 21, 2018; available online without subscription through the open access option. ©AlphaMed Press 1066-5099/2018/\$30.00/0.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1002/stem.2966

virus) and toll like receptor 4 (TLR4 - bacteria) is well established [5,6]. Recent publications in animal studies (mice and non human primates) indicate that there may be some immune response to autologous reprogrammed cells [7–14]. A recent review identified that many aspects of the adaptive and innate immune system mechanisms are yet to be explored in detail for human cells [3,15]. Data from human transplanted autologous reprogrammed cells *in vivo* is limited and only one current clinical trial for iPSC-RPE cells exists that found edema in the patient retina most likely from the surgical intervention for the transplanted iPSC-RPE cell sheet [16–19]. As the field grows and moves closer to clinical application the need to understand the extent of the immune response to transplanted human iPSC-derived cells becomes paramount.

Of the studies conducted to date in mouse models on the immune response to autologous iPSC-derived cells, the group from Zhao *et al* (2011) studied the immunogenicity of both retroviral vector reprogrammed mouse iPSC and episomal vector reprogrammed integration free mouse iPSC. They transplanted the mouse cells under the skin to evaluate the immunogenicity of mouse iPSC-derived cells in syngeneic mice and found issues with immunogenicity [8]. Studies that transplanted mouse iPSC-derived cells into the neural system and kidney found no apparent immunogenicity [7,9]. Further work by D. Todorova *et al* identified one possible mechanism underlying these conflicting conclusions [14]. They show that the lack of immunogenicity of mouse iPSC-derived cells in syngeneic host when transplanted into the kidney is due to the absence of functional antigen presenting cells in mouse kidney, highlighting that the site of iPSC-derived cell transplantation *in vivo* is important in experimental design<sup>14</sup>. A more recent study was performed in non-human primates testing iPSC-derived neurons found no major immune response, although a small immune response was observed [10]. In the study by Zhao *et al* (2015), iPSC-derived smooth muscle cells and retinal pigmented epithelial cells were transplanted into humanized mice reconstituted with autologous human immune system, demonstrating differential immunogenicity *in vivo*<sup>12</sup>. Interestingly, IL10 secretion from mouse iPSC-derived cells has been found to suppress the immune response, and IL10 is known to suppress the activity of activated T cells, suggesting a mechanism for iPSC-derived cells to by-pass immune system to survive and engraft [11].

There is a clear need to better understand what the immune response to human autologous reprogrammed cells will be before we embark on extensive clinical trials to treat human disease. We have performed a detailed global proteomic and methylome analysis of the possible immune response of matched human patient fibroblast cells (termed F1) reprogrammed to iPSC and compared to iPSC-derived cells (termed F2) for retroviral, episomal and synthetic mRNA transfection methods to reprogram human fibroblasts to human iPSC. The data shows that in most aspects the immune biology is similar for either viral or non-viral made iPSC-derived cells; however, a significantly different higher expression of wild type (WT) human toll-like receptor 3 (TLR3) in iPSC derived cells. Global methylome analysis in synthetic mRNA made human iPSC revealed a shorter isoform of human TLR3 is over expressed in human reprogrammed cells (the TLR3 isoform is not expressed in mice) not seen in normal human physiological tissues or cells. We confirm in three retroviral made and three

episomal made human iPSC from healthy control patient cells that the TLR3 isoform is over expressed in five from six matched pairs of cells (approx. 85% of human iPSC overexpress the human TLR3 isoform). We show that the human TLR3 isoform functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of human iPSC-derived cells to viral infection. Taken together the data demonstrate that the cell reprogramming process alters specific aspects of the immune response of *in vitro* generated human iPSC-derived cells, suggesting a reduction of innate immunogenicity of human iPSC-derived cells, calling for screening of human iPSC clones for human TLR3 expression levels before use in disease modeling or clinical applications.

## MATERIALS AND METHODS

### iPSC cell culture

Established human iPSC clones were obtained from collaborators for this project and previously published. Six human skin fibroblast cell lines (termed F1) that have previously been reprogrammed into iPSC, three by retroviral methods [20,21] [2] and three by non-viral episomal methods [22] were used. Synthetic mRNA reprogramming to iPSC was performed using Stemgent's microRNA-enhanced mRNA reprogramming kit (STEMGENT, #00–0071) protocol using Thermo Fischer defined cell culture media products. Differentiation to various cell lines and the mRNA transfection method is described in full in a separate manuscript. All hiPSC were differentiated between passages 10 to 15. Feeder-free "clinical grade" synthetic mRNA iPSC were cultured in defined Flex E8 culture medium (Life Technologies, A2858501) on Vitronectin (Life Technologies, A14700) coated plates. Colonies were passaged by gentle dissociation with 0.5 mM EDTA when they were 75%–80% confluence. Cell culture conditions for hiPSC can be found for Episomal and Retroviral made hiPSC in the papers from [20, 21 and 22].

### Proteomic analysis for Global and MHC1 peptide analysis

**Protein solubilisation and quantification.** Protein solubilisation was performed independently for each of the eight pelleted cell samples, five with patients fibroblasts (F1) and three with iPSC-fibroblasts (F2), with 1% (v/v) sodium dodecyl sulfate (SDS) lysis buffer. To eliminate viscosity the lysates were heated to 60°C for 15 minutes and sonicated at 45% amplitude for 4 s. Protein concentration of each sample was estimated using BCA Reagent Compatible kit (Thermo Scientific) following the manufacturer's instructions.

**Peptides preparation and labeling with Isobaric Tags (TMT 10-Plex).** For global analysis, 50 mg of proteins from each sample were digested and labeled with tandem mass tag (TMT) 10-plex isotopic label reagent set (Thermo Scientific, Rockford, IL, USA) following the manufacturer's instructions. Nine of the 10 TMT label reagents (tags: 126; 127 N; 127C; 128 N; 128C; 129 N; 129C; 130 N; 131) were used. For normalization purposes, an internal control consisting on a mixture of 6.25 mg of each of the eight samples was included and labeled with TMT126, The TMT labeled samples including control were then combined at a 1:1:1:1:1:1:1:1:1 ratio. Mixture of samples

was cleaned by Pierce C18 Spin columns (Thermo Scientific) and stored at  $-80^{\circ}\text{C}$ .

**Liquid Chromatography–Tandem Mass Spectrometry.** For global analysis, labeled peptides were separated by means of nanoliquid chromatography using a nanoLC ULTRA AS2 (Eksigent) with a flow rate of 400 nl/min, a C18 Pepmap 100 trap column (5  $\mu\text{m}$ , 100  $\text{\AA}$ , 300  $\mu\text{m}$  i.d.  $\times$  5 mm in length), and an Acclaim PepMap C18 analytical column (3  $\mu\text{m}$ , 100  $\text{\AA}$ , 75  $\mu\text{m}$  i.d.  $\times$  15 cm in length).

The following linear gradient, using solvent B (97% ACN, 0.1% formic acid) and solvent A (3% ACN, 0.1% formic acid), was used: 5–30% buffer B (140 min). MS/MS analysis was performed using an LTQ Orbitrap Velos (ThermoFisher Scientific) with a nanoelectrospray ion source with precursor ion selection in the Orbitrap at 30000 of resolution, selecting the 20 most intense precursor ions in positive ion mode. MS/MS data acquisition was completed using Xcalibur 2.1 (ThermoFisher Scientific). For identification of TMT labeled peptides, higher energy collisional dissociation (HCD) with 40% fixed collision energy (CE) was the fragmentation method used.

**Protein Identification and Quantification.** Data was processed using Proteome Discoverer 1.4.1.14 (Thermo Fisher Scientific). For database searching, raw mass spectrometry files were submitted to the in-house *Homo sapiens* UniProtKB/Swiss-Prot database (released 2015–02; 20,165 protein entries) using SEQUEST (Thermo Fisher Scientific). The Percolator search node, a machine-learning supplement to the SEQUEST search algorithm that increases the sensitivity and specificity of peptide identifications, was also used. Searches were performed using the following settings: 2 maximum miss cleavage for trypsin, TMT-labeled in N-Terminal, lysine (+229.163 Da) and methionine oxidation (+15.995 Da) as dynamic modifications, cysteine carbamidomethylation (+57.021 Da) as static modification, 20 ppm precursor mass tolerance, 0.05mmu fragment mass tolerance, 5mmu peak integration tolerance, and most confident centroid peak integration method. The criteria used to accept protein identification included a minimum of 2 peptides matched per protein, with a false discovery rate (FDR) of 1%. In order to avoid the possible ambiguity associated with different isoforms of the same protein during the quantification, all of the proteins were treated as ungrouped.

Quantitative analysis of the TMT experiments was performed simultaneously to protein identification using Proteome Discoverer software. Peptide spectral matches (PSMs) were filtered by PD1.4 software with parameters: Min. Precursor Mass: 300 Da, Max. Precursor Mass: 5000 Da. Reporter ion quantification of HCDMS2 spectra was enabled, and TMT-10 plex was set as quantification method. To avoid overlap between the isobaric reporter ions a resolution greater than 60,000 was used from  $m/z$  126.1 to  $m/z$  131.1. The quantification values were extracted from the ration between the reporter ions intensities (in; where n represents the reporter ions ranging from  $m/z$  127.1 to  $m/z$  131.1) and the reporter ion intensity from  $m/z$  126.1, and were corrected according to the isotopic purities of the reporter ions provided by the manufacturer. Quantification values were rejected whenever any quantification channel was missing or whenever variability of the reporter intensity was higher than 50% among the

different PSMs of the same protein. For protein quantification purposes, only unique peptides were considered, and protein ratios were normalized to protein median. Normalized values for each protein were exported to Microsoft Excel (v14.0.0), and only those proteins with quantification values for all of the samples (i.e., 8 samples and the internal control) were considered for further analysis.

**Illumina Infinium Methylation EPIC BeadChip.** All DNA samples were assessed for integrity, quantity and purity by electrophoresis in a 1.3% agarose gel, picogreen quantification, and nanodrop measurements. Bisulfite conversion of 500 ng of genomic DNA was performed using EZ DNA methylation kit (Zymo Research, Irvine) following manufacturer's instructions. 200 ng of bisulfite converted DNA were used for hybridization on the Illumina Infinium MethylationEPIC BeadChip (Illumina, Inc. San Diego). Briefly, samples were whole genome amplified followed by an enzymatic end-point fragmentation, precipitation and resuspension. The resuspended samples were hybridized onto the beadchip for 16 hours at  $48^{\circ}\text{C}$  and washed. A single nucleotide extension with labeled dideoxy-nucleotides was performed and repeated rounds of staining were applied with a combination of fluorescently labeled antibodies differentiating between biotin and DNP. Fluorescent signal from the microarray was measured with a HiScan scanner (Illumina, Inc. San Diego) using iScan Control Software (V 3.3.29).

A three step-based normalization procedure was performed using the lumi [34] package available for bioconductor [35], under the R statistical environment, consisting in color bias adjustment, background level adjustment and quantile normalization across arrays, as specified in [34]. Methylation level ( $\beta$ -value) for each of the 866,836 CpG sites were calculated as the ratio of methylated signal divided by the sum of methylated and unmethylated signals plus 100. All beta values with an associated p-value greater or equal to 0.01 were removed from the analysis.

**Bisulphite Pyrosequencing.** To validate the methylome array, we performed bisulphite pyrosequencing following published protocols [36]. Briefly, specific set of primers for PCR amplification and sequencing were designed using the PyroMark assay design program, version 2.0 (Qiagen); amplification primers hybridize with CpG-free sites to ensure a methylation-independent reaction and one primer (opposite the sequencing primer) is biotinylated to convert the PCR product to single-stranded DNA templates. We used 1  $\mu\text{l}$  of bisulphite-treated DNA for each PCR. The EZ DNA methylation kit (Zymo Research) was used for bisulphite conversion of all DNA samples used [36]. In order to prepare single-stranded PCR products, we used the Vacuum Prep Tool (Qiagen), following the manufacturer's instructions. Pyrosequencing reactions and methylation quantification were performed in a PyroMark Q24 System version 2.0.6 (Qiagen).

**Sequencing.** Human TLR3 isoform was sequenced using 50 ng of DNA following a BigDye protocol published by the University of Pompeu Fabra Genomics Core Facility in Barcelona. Primers used listed in Supplementary Figures.

**Lipopolysaccharide (LPS) and Poly (I:C) stimulation.** F1 and F2 cells were seeded in 24-w plate and once 80% confluent

they were stimulated with 100 ng/ml lipopolysaccharides (LPS) and 1 µg/ml Polyinosinic:polycytidylic acid, (Poly(IC)), to stimulate an innate immune response. After 24 h supernatants were collected and analyzed with an illumina cytokine kit. Cells were also pelleted and protein lysates were extracted and separated into cytoplasmic and nuclear fraction.

**Cytoplasmic and nuclear protein fraction extraction.** Cells were resuspended on 80 µl of Buffer A (HEPES 10 mM pH 7.9, KCl 10 mM, MgCl<sub>2</sub> 1.5 mM, DTT 1 mM) with protease inhibitors (PMSF 0.5 mM, aprotinin 5 µg/ml, leupeptin 2 µg/ml, sodium pyrophosphate decahydrate 2 mM, sodium beta-glycerophosphate pentahydrate 2 mM, sodium orthovanadate 1 mM). It was kept on ice for 15 min, then NP40 0.6% was added and centrifuged 30s 16.000 g at 4°C. The supernatants (cytoplasmic fraction) were transferred to a new tube. Cell pellets (nuclear fraction) was resuspended in 50 µl of Buffer B (HEPES 20 mM pH 7.9, NaCl 0.46 M, EDTA 1 mM, EGTA 1 mM, DTT 1 mM) with PMSF.

**Illuminex cytokine detection array.** Cytokine levels was assessed by Luminex (Millipore, Billerica, MA, USA) following the manufacturer's instructions. Briefly, supernatants were incubated for 2 h with corresponding anticytokine magnetic beads, and then washed with 1x washing buffer and stained with detection antibodies (provided) for 1 h. Streptavidin-PE was then added for 30 more minutes. During all incubation steps the plate was agitated at 650 rpm. After washing, plate was agitated for 15 minutes at 650 rpm and read in the xMAP Luminex reader (Waltham, MA, USA).

**Lentiviral production.** Human wild type TLR3 Lentiviral Vector was purchased (pLenti-GIII-UbC) (Abcam, LV335740) and was used to overexpress human TLR3 full length in iPSC-derived NSC (NSC). Viral particles were produced with a 293 T packaging cell line. NSC were infected once with viral supernatants. At day 3, infected NSC were selected with puromycin for seven days and placed in experiments. Overexpression of TLR3 was checked by RT-PCR, FACS and western blot.

**Western Blot.** Protein extracts of cells collected by centrifugation, washed twice in PBS, lysed in 1x lysis buffer (50 mM Tris-HCl, 70 mM 2-mercaptoethanol, and 1% sodium dodecyl-sulfate (SDS) and the concentration of total protein was measured by the Bradford assay. Lysates were then boiled for 5 min, and subjected to 12% polyacrylamide SDS gels or 4%–12% SDS resolving gels (Invitrogen). After electrophoresis, proteins were transferred to a nitrocellulose membrane using a submerged transfer apparatus (BioRad), filled with 25 mM Tris Base, 200 mM glycine, and 20% methanol. After blocking with 5% non-fat dried milk in TBS-T (50 mM Tris- HCl [pH 8.0], 150 mM NaCl, and 0.1% Tween 20) the membrane was incubated with the primary antibodies diluted in TBS-T and washed extensively. For the list of primary antibodies used see **Supplementary Figure 10**. The membrane was washed 3 times with TBS-T and then incubated with the appropriate horseradish peroxidase linked secondary antibody (Amersham). The detection was performed with the Western Breeze Immunodetection Kit (Invitrogen).

**Flow cytometry.** Cells were stained with antibodies listed in figures. All analyses were performed with a *BD FACSCanto-II flow cytometer* or MoFlo cell sorter (Dako Cytomation) running Summit software. See **supplemental Figure 9** for list of antibodies used.

**Real Time PCR.** Total mRNA was isolated using TRIZOL and 1 µg was used to synthesize cDNA using the Invitrogen Cloned AMV First-Strand cDNA synthesis kit. One to two µl of the reaction was used to quantify gene expression by qPCR for genes listed in the table below.

human TLR3	CCTGGTTTGTAAATTGGATTAACGA	TGAGGTGGAGTGTTCAAAGG
human TLR4	CCAGTGAGGATGATGCCAGAAT	GCCATGGCTGGATCAGAGT
human TLR3 short	Isoform	
human HLA A	AAGACACAACCAGGAAGTCC TCCTGGAGCTGTGATCGCT	GCTTCTGACTTCCAGTCC AAGGGCAGGAACAACCTTG
human HLA B	TCCTAG CAGTTGTGGTCATC	TCAAGCTGTGAGAGACACAT
human HLA C	TCCTGGTTGCTCTAG CTGTC	CAGGCTTACAAGTGATGAG
human B2M	TGACTTTGTCACAG CCCAAGATA	AATCCAAATGCG G CATCTTC
human	GAPDH	GCACCGTCAAGGCTGAGAAC
	AGGGATCTCGCTCCTGGAA	

TLR3 isoform RT-PCR primers were tested in both HFF cells and NSC with R<sup>2</sup> of 0.78465 and 0.92829, respectively (**Supplementary Fig. 10**). All other primer sets are previously published.

**Statistical Analyses.** Unpaired nonparametric t-tests were used to evaluate statistical significance at p ≤ .05. All quantitative and qualitative analyses are representative of at least n = 3 biological repeats for all experiments to give significant statistical power for reliability and validity of data. Only significantly different data in the figures are given a p value. **Differential Protein Annotation and Bioinformatics Analyses:** Proteins identified in different amounts in each of the two experiments were analyzed using the bioinformatics tool DAVID v6.7 (Database for Annotation, Visualization and Integrated Discovery; <http://david.abcc.ncifcrf.gov/>) in order to identify overrepresented biological pathways [37,38]. Similarly, differential proteins were analyzed for protein–protein interaction networks using the online tool STRING v10 [39]. To determine differentially expressed quantified proteins between the groups (F1 versus F2) for small peptide analysis, statistical analysis was carried out using SPSS for Windows (version 21.0, Chicago, IL, USA). All variables were checked for Levene's test to check variance homogeneity. Comparison between groups (i.e., F1 vs F2) was performed using Student's t-test. p ≤ .05 was considered to be significant.

## RESULTS

### Global proteomic analysis of patient (F1) and iPSC-derived fibroblasts (F2)

Six human skin fibroblast cell lines (termed F1) that have previously been reprogrammed into iPSC, three by retroviral methods [20,21] [2] and three by non-viral episomal methods [22], then differentiated back to fibroblasts (termed F2) were analyzed for their potential immune response (Fig. 1A).

First, we performed a global proteomic analysis comparing F1 to F2 cells and mapped the protein expression profile. Overall, we detected 1,508 quantifiable proteins of which 86 proteins differed significantly in the expression levels between F1 and F2 cells (Supplementary Fig. 1 and 2). Categorizing proteins based on function, we first demonstrate no significant difference in fibroblast markers CD90, Fibronectin and CD44 between F1 and F2 cells, indicating that they are similar fibroblast cell populations for both viral and non-viral made iPSC-derived cells (Fig. 1B). CD90, CD44 and Fibronectin are established markers of fibroblasts as defined by Darrell Pilling et al, 2009 [23]. The main differences in protein expression in F2 cells are signal transduction, cell cycle, and immune system proteins (Fig. 1C-1G; Supplementary Fig. 1A). Interestingly, the proteomic screen revealed many proteins interacting with the toll-like receptor TLR3 and TLR4 pathway (Fig. 1F-1G).

To verify the global proteomic analysis we performed flow cytometry analysis of the F1 and F2 populations and confirmed that the two fibroblast cell populations are similar for two fibroblast cell markers CD90, CD44 and negative for stem cell marker CD34 (Fig. 1H). This was the same for retrovirally made iPSC-derived cells or non-virally made iPSC-derived cells and so they are both grouped together (Supplementary Fig. 3). Given that signal transduction proteins were the most represented differentially expressed proteins between F1 and F2 cells, we also verified that signal transduction pathways for AKT is over expressed in F2 cells compared to F1 cells by western blot analysis (Fig. 1I). We next assessed the immune response given the differences identified in the proteomic screen.

### Characterization of adaptive and innate immune system in human iPSC

Analysis of HLA type by deep sequencing methods was performed to confirm the HLA type for all cell types used (Fig. 2A). MHC1 mRNA gene expression (HLA-A, B, C and B2M) for F1, iPSC and F2 cells by RT-PCR and demonstrates no significant change in expression between F2 cells and F1 cells (Fig. 2B), supported by similar results in a previously published report [24]. MHC1 protein expression was assessed by flow cytometry in all F2 cell lines and no significant difference in expression levels of MHC1 was observed. Expression of MHC1 was not significantly different between retrovirally made iPSC-derived cells (RV1-3) and non-virally made iPSC-derived cells (Epi1-3) (Fig. 2C).

To mimic the possible *in vivo* functional response, we assessed MHC1 expression response to inflammation cytokine INF-gamma (10 ng/ml over 24 hrs.) in F1 and F2 cells from both viral and non-viral made iPSC by flow cytometry. Both F1 and F2 cells responded with an upregulation of MHC1 expression in response to INF-gamma and there was no significance difference indicating that the regulation of MHC1 expression is

not affected in iPSC derived cells (Fig. 2D and Supplementary Fig. 4). This suggests further that MHC1 expression is functionally normal in iPSC-derived cells.

To further characterize the F1 and F2 cells we analyzed the expression of small peptides presented by MHC1 using mass spectrometry for RV1 clone that revealed differences in the number and type of small peptide expressions between F1 and F2 cells that could implicate functional differences in the adaptive immune response of transplanted iPSC-derived cells (Supplementary Fig. 5).

We next analyzed the innate immune response by assessing the expression of 25 cytokines routinely assayed by clinical immunologists using the Elisa method in 2 matched cell lines (F1 vs. F2 cells) for viral (RV) or non-viral (EPI) made iPSC derived cells, with or without viral ligand stimulation (Poly IC) or bacterial ligand stimulation (LPS) identified the main cytokines involved (Supplementary Fig. 6A). Further analysis in another focused cytokine array (6 cytokines) assessing four matched iPSC lines (F1 vs. F2 cells), we found no significant difference in expression of cytokines between viral and non-viral made F2 cells when compared to F1 cells. In general, we found high variation between patient cell lines in cytokine levels that suggested altered expression in F2 cells (Supplementary Fig. 6).

We found proteins associated with the innate immune system with higher wild type (WT) human toll-like receptor 3 (TLR3) and wild type (WT) toll-like receptor 4 (TLR4) expression found in the proteomic screen in F2 cells (Fig. 1) suggesting a dysfunctional innate cell signaling pathway, prompted us to investigate further human TLR3 expression levels in the healthy patient control matched F1 and F2 cells (Fig. 1 and Supplementary Fig 1-2). We observed that four from five patient (80%) control F1 matched F2 cells have increased TLR3 gene expression in F2 cells by RT-PCR analysis (Fig. 2E and Supplementary Figure 7B.). We next confirmed by flow cytometry analysis TLR3 receptor protein expression is independent of method used to reprogram cells and overexpressed in F2 cells (Fig. 2F). Taken together the data demonstrate that the WT TLR3 receptor expression is higher in healthy patient control iPSC-derived cells, suggesting that reprogrammed cells have an altered TLR3 pathway.

### Human TLR3 isoform transcription start site is hypomethylated in human iPSC-derived cells and exclusively expressed in humans

To investigate further the increase in TLR3 expression in a wide range of iPSC-derived cell types, we reprogrammed using non-viral synthetic mRNA transfection methods human foreskin fibroblasts (HFF) (F1) and characterized six iPSC clones differentiated to various cell types (F2) (iPSC characterization data in a separate submitted paper) (Fig. 3-5). We then performed a methylome array to further characterize and better define the differences between F1 and F2 cells (Fig. 3A). Using the following bioinformatic criteria: (i) more than 20% difference in CpG methylation levels, (ii) more than one CpG island affected and (iii) at least 2 hiPSC clones affected, we analyzed the methylation levels for Toll-like receptors (Fig. 3B). Interestingly, the methylome array detected that a transcription start site (TSS) site in the CpGs of a shorter genetic isoform of full length TLR3 gene, and not other TLR gene family members (Supplementary excel methylome data), is hypomethylated in

human iPSC and derived NSC (F2), not seen in the starting parent HFF cells (F1) (Fig. 3B). We confirmed the CpG hypomethylation of the TLR3 isoform by bisulfite pyrosequencing (Fig. 3C and Supplementary Fig. 7). Bioinformatics analysis of the human TLR3 WT and TLR3 Isoform demonstrate that the TSS site is associated with Acetylation and DNase hypersensitivity sites associated with gene expression and that the TLR3 isoform is uniquely expressed in humans and not in mice or rat (Fig. 3D and 3E).

### Human TLR3 isoform is overexpressed in most human iPSC-derived cells not seen in normal human tissue or cells

We next assessed gene expression levels of human TLR3 isoform in human F1 and F2 cells from the healthy patient control cells (Episomal and Retroviral) described in Figures 1 and 2 and the synthetic mRNA made human iPSC cells described in Figure 3. We next performed PCR of genomic DNA for sequencing in F2 cells from synthetic mRNA made human iPSC-derived: neural stem cells (NSC) and cardiomyocytes (CM) to demonstrate the unique 5' UTR of the human TLR3 isoform in F2 cells. Sequencing data of the PCR product for the 5' UTR confirms the human TLR3 isoform (in Red) in human F2 cells with whole sequence found at UC011CKZ.2 or XM\_017008577.1 transcript variant X1 (Fig. 4A). We next tested protein expression of the human WT TLR3 and shorter TLR3 isoform by western blot in F1 and F2 cells (from synthetic mRNA made human iPSC-derived) demonstrating expression of the WT TLR3 at 107 KDa and the putative shorter TLR3 isoform at approximately 80 KDa missing the LRR1-8 region important in receptor stabilization (Fig. 4A and Supplementary Fig. 8).

We next performed a comprehensive analysis of human TLR3 gene expression levels in normal endogenous cell lines or normal human neural tissue (frontal cortex or Hippocampus) compared to various human iPSC derived cell types (from synthetic mRNA method) to further confirm overexpression in human iPSC derived cells (F2) and that differentiation or reprogramming method does not affect TLR3 expression levels (Fig. 4B). RT-PCR gene expression analysis revealed that the shorter TLR3 isoform is lower expressed in F1 cells than WT TLR3 and is significantly higher upregulated in all reprogrammed differentiated F2 cell types (Cardiomyocytes – CM,  $p = .0093$ ; Definitive Endoderm – DE,  $p = .033$ ; Neural Stem Cells – NSC,  $p = .0044$  and Motor Neurons – MN,  $p = .013$ ) (Fig. 4C). Interestingly, in addition to human foreskin fibroblasts (HFF) other normal endogenous cells such as bone marrow mesenchymal stem cells (BM MSC), umbilical stem cells (USSC) or normal human brain tissue (hippocampus and frontal cortex) have low levels of expression of WT TLR3 and the shorter isoform TLR3, suggesting only reprogrammed iPSC-derived cells have elevated levels of the TLR3 isoform (Fig. 4C).

Therefore, we demonstrate that the over expression of the shorter TLR3 isoform in iPSC-derived cells is independent of the methodology used because high levels of the isoform have been found in most human iPSC generated by three different methods (retrovirus, episomal vectors, or mRNA transfections). Moreover, higher expression of the TLR3 isoform is independent of the starting parent cell types because all somatic cell types we tested, including human foreskin fibroblasts, cord blood cells, patient skin fibroblasts, mesenchymal stem cells

had low levels of expression of the human TLR3 isoform. Finally, the differentiation method did not affect levels of the TLR3 isoform expression because we generated many different cell types from iPSC (F2 cells included fibroblasts, neural stem cells, motor neurons, cardiomyocytes and definitive endoderm cells) and most had significantly higher levels of expression of the TLR3 isoform (Fig. 4B and C).

Given that it has been previously published that a short isoform of mouse TLR3, but different sequence and size to the human TLR3 isoform described in this study can act as a suppressor of the TLR3 innate immune pathway by competing with the full length TLR3 protein in mouse astrocytes [25–27], we next assessed the functional immune response of inflammation cytokine IL6 in human iPSC-NSC to Poly (I:C) and LPS. Assessment of IL6 expression levels by ELISA demonstrated that iPSC-derived cells (F2 cells) have significantly higher levels of expression of IL6 compared to F1 cells and a suppressed innate immune response to viral infection (Poly IC 1ug/ml overnight) in iPSC-derived cells (Fig. 4D). This suggests that transplanted human iPSC-NSC would act as a cellular pump producing physiologically higher levels of IL6 cytokine than is normal in circulating blood and tissues and the cells would not respond to viral infection (Fig. 4D).

### Human TLR3 isoform functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC)

Next, we performed a gain of function test in human iPSC-NSC (F2 cells) to demonstrate the possible functional effect of the human TLR3 isoform. We overexpressed WT TLR3 by lentiviral methods in five synthetic mRNA made iPSC-NSC clones to out-compete the TLR3 isoform and all NSC clones demonstrated high levels of WT human TLR3 expression after infection (Fig. 5A). Analysis of the expression of nuclear NF-KB p65 protein phosphorylation by western blot, an established marker of a functional human TLR3 pathway, demonstrated that overexpression of human WT TLR3 in NSC could return sensitivity to Poly (IC) treatment of NSC (Fig. 5B). Note that in control NSC cells and in empty lentiviral control NSC (UB promoter only) the NSC do not respond to Poly IC viral stimulation demonstrated by no change in NF-KB p65 phosphorylation levels (Fig. 5B). Overexpression of WT TLR3 in NSC and resulting return to sensitivity to Poly IC stimulation supports the model that the shorter TLR3 isoform is suppressing normal TLR3 function in NSC to viral insult (F2 cells) (Fig. 5B). Taken together, we propose the model that in human iPSC-derived cells that overexpress the shorter isoform of TLR3 competes with full length TLR3 to suppress the innate inflammation signal transduction response in F2 cells to Poly IC (viral infection) (Fig. 5C).

## DISCUSSION

There is a clear need to better understand the immune response of autologous reprogrammed human cells generated *in vitro* before we embark on extensive clinical trials using human iPSC to study and treat human disease. With that in mind we posit the question: do patient cells that have been reprogrammed into iPSC-derived cells cause an immune response?

This study is based on a global proteomic and methylome screening we performed using human skin cells (termed F1 cells) compared to their iPSC-derived cells (F2 cells) made from three different reprogramming methods (retroviral, episomal and synthetic mRNA transfection). We reveal that wild type (WT) TLR3 and a isoform of TLR3 are overexpressed in the majority (83%) of F2 cells tested (five from six F1-F2 match lines tested) and in all types of iPSC-derived cells (neural stem cells, motor neurons, definitive endoderm and cardiomyocytes) warranting screening of iPSC-derived cell clones and removal in disease modeling studies or clinical applications (Fig. 2D, 3B and 3C).

The data demonstrate that the cell reprogramming process alters specific aspects of the innate immune response resulting in a possible suppression of immunogenicity, supporting similar findings recently described for human iPSC-derived cells [11,28]. We discover two distinct states in human iPSC-derived cells related to overexpression WT TLR3 and Isoform TLR3 that could impinge on future clinical applications and disease modeling:

- a. Unstimulated state: increased IL6 associated with increased WT TLR3 expression in F2 cells (iPSC-derived cells) (Fig. 4C-D).
- b. Stimulation with Poly IC: suppressed response to Poly IC (Virus) in F2 cells due to overexpression of an isoform TLR3 that can be rescued by overexpression of WT TLR3 (Fig. 5A-C.).

The higher levels of expression of the human toll-like receptor 3 (TLR3) isoform is central to understanding the altered immunogenicity of human iPSC-derived cells. To mediate innate immune response to virus infection and consequently the virus immunogenicity, double-stranded RNA (dsRNA), a frequent by-product of virus infection, should be recognized by toll-like receptor 3 (TLR3). Simultaneously, the PI3K-Akt (Fig. 1I) and NF- $\kappa$ B (Fig. 5B) pathways play an essential role in TLR3-mediated gene induction [29]. The loss of inflammation response of cells to bacterial (LPS) or viral (Poly IC) infection has been shown before in specific mouse neural cell types that overexpress a different mutant mouse TLR3 isoform to the human TLR3 isoform described in this study (not expressed in mice) [25–27]. Interestingly, a recent study found that differentiation of human iPSC results in a loss of immunogenicity and leads to the induction of tolerance, despite expected antigen expression differences between iPSC-derived versus original somatic cells [11]. In further agreement with this study it has also been demonstrated that neural progenitor cells from human induced pluripotent stem cells generated less autogenous immune response, possibly by altered toll like receptor pathway signaling they did not assess [28]. This observation among others brings forward the interesting possibility that human iPSC-derived cells may benefit from a suppressed immunogenic microenvironment favoring initial survival and subsequent engraftment and tissue regeneration.

Research in animal models is well documented and work by Araki et al, working mainly with skin and bone marrow transplant in mice, demonstrates mouse iPSC-derived cardiomyocytes cause T cell infiltration when transplanted under the skin of syngeneic mice [13]. Todorova et al, found that the location of iPSC transplantation can affect the immune

outcome because the kidney is immune privileged, highlighting that differences between studies could be explained by experimental procedure and design differences<sup>14</sup>. The group by Almeida et al, found that mouse iPSC-derived endothelial cells are intrinsically immunogenic in syngeneic mice, but are immune tolerated by overexpressing immune suppressive molecule IL-10; however, their study did not assess TLR3 expression levels [11].

The altered TLR3 innate immune response of human *in vitro* iPSC-derived cells raises a number of issues to be considered for future cell transplantation in humans.

- i. This may allow for human iPSC-derived cells to be used not only as an autologous cell therapy but also in a limited capacity as an allogenic cell therapy because of a suppressed immunogenic microenvironment favoring initial survival and subsequent engraftment and tissue regeneration.
- ii. Evasion of the immune system is a key hallmark of cancer and suppression of the immune response of iPSC-derived cells may impose a long-term cancer threat not previously considered. This consideration is considerably enhanced by recent work that demonstrates the AKT pathway induces a transcriptional program via C/EBP that promotes immune suppression during inflammation and tumor growth [30]. Inhibition of the AKT driven signaling pathway prolongs NF $\kappa$ B activation, which in turn inhibits C/EBP $\beta$  activation promoting an immunostimulatory transcriptional program that restores CD8+ T cell activation, cytotoxicity and synergizes with checkpoint inhibitor therapy to promote tumor regression and extend survival in mouse models of cancer [30].
- iii. Transplantation of iPSC-derived cells that constitutively express physiologically higher levels of inflammatory cytokine IL6 (Fig. 4D) may result in long-term adverse effects in the body. This may have important implications in future human iPSC clinical trials such as the RIKEN AMD-RPE clinical trial [17,18].
- iv. The need to screen patient iPSC and derived cells using global gene analysis “omics” for alterations in the genome of patient cells that include expression levels of TLR3 and its shorter TLR3 isoform identified in this work. Indeed, impaired TLR3 function to herpes simple virus (HSV-1) infection in the CNS has important implications in the pathogenesis of HSV-1 encephalitis (HSE) in children [31].

Interestingly, activation of innate immunity is required for efficient nuclear reprogramming to iPSC via the TLR3 receptor pathway using either viral or non-viral methods [32]. The authors find that by using gain and loss of function studies, the TLR3 pathway enables efficient induction of pluripotency by viral or non-viral synthetic mRNA transfection approaches. Stimulation of TLR3 causes rapid and global changes in the expression of epigenetic modifiers to enhance chromatin remodeling and nuclear reprogramming. Furthermore, they conclude that activation of inflammatory pathways are required for efficient nuclear reprogramming in the induction of pluripotency [32]. Our finding suggests that the TLR3 pathway, important for achieving cell pluripotency, is not re-set to the correct expression levels in iPSC-differentiated cells (F2) and that this then results in altered cytokine secretion leading to possible immune suppression of transplanted iPSC-

derived cells (Fig. 4 and 5). We demonstrate that the mechanism of constitutive expression of the shorter TLR3 isoform is most likely at an epigenetic level, resulting in hypomethylation of a transcription start site producing a shorter TLR3 isoform that competes to suppress normal full length TLR3 signal transduction function (Fig. 3 and 4).

In conclusion, the data demonstrate that the cell reprogramming process alters the immune response of most iPSC-derived cells highlighting human TLR3 isoform over expression that functions to suppress innate immune signal transduction and provides an insight for future clinical applications of autologous human iPSC-derived cell transplantation. We propose that screening human iPSC clones and their derived cells for alterations in the genome of patient cells that include expression levels of human TLR3 and its shorter TLR3 isoform identified in this work is essential before embarking on “first in man” clinical trials or human disease modeling using human iPSC.

#### ETHICAL STATEMENT

Use of human iPSC and tissue obtained by collaborators from published work funded by CEIC approved projects 2012-StG-311,736-PD-HUMMODEL, BFU2016-80870-P), Red de Terapia Celular - TerCel RD16/0011/0024 and BFU2011-26596<sup>12, 13 2</sup> [14].

#### ACKNOWLEDGMENTS

The authors acknowledge the support of the following people: Angel Raya Centre for Regenerative Medicine Barcelona (CMRB), John Christodoulou of the University of Sydney, Eduard Palou Rivera for HLA analysis, Josep Maria Estanyol of the Technological and Scientific Centre at the University of Barcelona, a member of the ProteoRed network (<http://www.proteored.org/>) for assistance in the proteomic analysis, Montserrat Pau for technical assistance, Carmen Barrot for RT-PCR analysis. Isabel Crespo Torres, Responsable Plataforma Citometria IDIBAPS. MJE is supported in part by the Program Ramon y Cajal (RYC-2010-06512), FBG project 307900, MINECO project grant BFU2011-26596, BFU2014-54467-P, TV3 Marato project grant /FBG309768 and Talent Retention program, University of Barcelona. The proteomic analysis was supported by projects from the Ministerio de Economica y Competitividad P113/00699 and EU-PF7-PEOPLE-2011-ITN289880 to RO. Dr. Manel Esteller laboratory is supported by, among other institutions, the EU Joint Programme – Neurodegenerative Disease Research (JPND); Cellex Foundation; the Health and Science Departments of the Catalan Government (Generalitat de Catalunya); the E-Rare (ERA-Net for research programs on rare diseases) and EuroRETT (a European network on Rett syndrome, funded by the European Commission under its 6th Framework

Program since 2006). Dr. Manel Esteller is an ICREA Research Professor. Antonella Consiglio: European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the Spanish Ministry of Economy and Competitiveness-MINECO (BFU2016-80870-P), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024), AGAUR (2014-SGR-1460).

#### AUTHOR CONTRIBUTIONS

J. Requena: Cell culture, RT-PCR, western blot, data analysis, TLR3 Lentiviral infection, figure preparation, manuscript preparation.

A. B. Alvarez-Palomo: Cell culture, RT-PCR, data analysis, manuscript preparation.

M. Codina-Pascual: Proteomic screen, data analysis, manuscript preparation.

I. Alvarez: MHCI small peptide analysis, data analysis, manuscript preparation.

M. Sal: Cell culture, RT-PCR, Data analysis, manuscript preparation.

R. Delgado-Morales, S. Moran and M. Esteller: Epigenetic analysis, Methylome array and Bioinformatics for Figure 3.

M. Juan Otero: ELISA, Data analysis, idea for Figure 3, manuscript preparation.

A. Boronat Barado: ELISA, Data analysis, Flow cytometry for Figure 1 and 2.

A. Consiglio: Provided iPSC F1 and F2 cells, human neural tissue sample, TLR3 lentiviral production, manuscript preparation.

O. Addeleccia Bogle: Proteomic screen, data analysis and figure preparation.

E. Wolvertang: Provided iPSC F1 and F2 cells, manuscript preparation.

D. Ovchinnikov: Provided iPSC F1 and F2 cells, manuscript preparation.

D. Jaraquemada: Idea for MHCI small peptide analysis, data analysis, manuscript preparation.

R. Oliva: Proteomic screen supervision, data analysis and manuscript preparation.

J. Mezquita Pla: Gene expression data analysis, PCR methodology, primer design, Figure design and preparation for Figure 3 and 4.

M. J. Edel: Original idea and overall project design, cell culture, flow cytometry, data analysis, funding, wrote the manuscript, Figures 1–5 preparation, coordination of national and international teams.

#### DISCLOSURES

All author declared no conflict of interest.

#### REFERENCES

1 Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;131:861–872.

2 Edel MJ, Menchon C, Menendez S et al. Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1. *Genes Dev* 2010;24:561–573.

3 Palomo AB et al. The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation. *J Clin Med* 2014;3:373–387.




- 4 Hoffmann JA, Kafatos FC, Janeway CA et al. Phylogenetic perspectives in innate immunity. *Science* 1999;284:1313–1318.
- 5 Romieu-Mourez R, Francois M, Boivin MN et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. *J Immunol* 2009;182:7963–7973.
- 6 Bai W, Liu H, Ji Q et al. TLR3 regulates mycobacterial RNA-induced IL-10 production through the PI3K/AKT signaling pathway. *Cell Signal* 2014;26:942–950.
- 7 Liu P, Chen S, Li X et al. Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells. *PLoS One* 2013;8:e69617.
- 8 Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. *Nature* 2011;474:212–215.
- 9 Guha P, Morgan JW, Mostoslavsky G et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. *Cell Stem Cell* 2013;12:407–412.
- 10 Morizane A, Doi D, Kikuchi T et al. Direct Comparison of Autologous and Allogeneic Transplantation of iPSC-Derived Neural Cells in the Brain of a Nonhuman Primate. *Stem Cell Reports* 2013;1:283–292.
- 11 de Almeida PE et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. *Nat Commun* 2014;5:3903.
- 12 Zhao T, Zhang ZN, Westenskow PD et al. Humanized Mice Reveal Differential Immunogenicity of Cells Derived from Autologous Induced Pluripotent Stem Cells. *Cell Stem Cell* 2015;17:353–359.
- 13 Araki R, Uda M, Hoki Y et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. *Nature* 2013;494:100–104.
- 14 Todorova D, Kim J, Hamzeinejad S et al. Brief Report: Immune Microenvironment Determines the Immunogenicity of Induced Pluripotent Stem Cell Derivatives. *Stem Cells* 2016;34:510–515.
- 15 Hew M, O'Connor K, Edel MJ et al. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. *J Clin Med* 2015;4:1193–1206.
- 16 Mandai M, Kurimoto Y, Takahashi M. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. *N Engl J Med* 2017;377:792–793.
- 17 Mandai M, Watanabe A, Kurimoto Y et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. *N Engl J Med* 2017;376:1038–1046.
- 18 Kamao H, Mandai M, Okamoto S et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. *Stem Cell Reports* 2014;2:205–218.
- 19 Alvarez Palomo AB, McLenachan S, Chen FK et al. Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration. *Fibrogenesis Tissue Repair* 2015;8.
- 20 Sanchez-Danes A et al. Efficient Generation of A9 Midbrain Dopaminergic Neurons by Lentiviral Delivery of LMX1A in Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. *Hum Gene Ther* 2012;23:56–69.
- 21 Sanchez-Danes A et al. Disease-specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson's disease. *EMBO Mol Med* 2012;4:380–395.
- 22 Briggs JA, Sun J, Shepherd J et al. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. *Stem Cells* 2013;31:467–478.
- 23 Pilling D, Fan T, Huang D et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. *PLoS One* 2009;4:e7475.
- 24 Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. *Proc Natl Acad Sci U S A* 2002;99:9864–9869.
- 25 Farina C, Krumbholz M, Giese T et al. Preferential expression and function of Toll-like receptor 3 in human astrocytes. *J Neuroimmunol* 2005;159:12–19.
- 26 Seo JW, Yang EJ, Kim SH et al. An inhibitory alternative splice isoform of Toll-like receptor 3 is induced by type I interferons in human astrocyte cell lines. *BMB Rep* 2015;48:696–701.
- 27 Yang E et al. Cloning of TLR3 isoform. *Yonsei Med J* 2004;45:359–361.
- 28 Huang K, Liu PF, Li X et al. Neural progenitor cells from human induced pluripotent stem cells generated less autogenous immune response. *Sci China Life Sci* 2014;57:162–170.
- 29 Sarkar SN, Peters KL, Elco CP et al. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. *Nat Struct Mol Biol* 2004;11:1060–1067.
- 30 Kaneda MM, Messer KS, Ralainirina N et al. PI3Kgamma is a molecular switch that controls immune suppression. *Nature* 2016;539:437–442.
- 31 Lafaille FG, Pessach IM, Zhang SY et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. *Nature* 2012;491:769–773.
- 32 Lee J, Sayed N, Hunter A et al. Activation of innate immunity is required for efficient nuclear reprogramming. *Cell* 2012;151:547–558.
- 33 McLenachan S, Menchon C, Raya A et al. Cyclin A(1) Is Essential for Setting the Pluripotent State and Reducing Tumorigenicity of Induced Pluripotent Stem Cells. *Stem Cells Dev* 2012;21:2891–2899.
- 34 Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 2008;24:1547–1548.
- 35 Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 2004;5:R80.
- 36 Bibikova M, Ie J, Barnes B et al. Genome-wide DNA methylation profiling using Infinium(R) assay. *Epigenomics* 2009;1:177–200.
- 37 Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009;37:1–13.
- 38 Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44–57.
- 39 Szklarczyk D, Franceschini A, Wyder S et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res* 2015;43:D447–D452.




See [www.StemCells.com](http://www.StemCells.com) for supporting information available online.


**Figure 1. Global proteomic analysis of patient (F1) and human iPSC derived fibroblasts (F2).** (A) Panels left to right: Photos representative of the healthy control human fibroblasts termed F1 (human skin fibroblasts), iPSC clone (from previously published studies), differentiation to embryoid bodies (EB) and iPSC-derived fibroblasts, termed F2, at two different passages. A total of six sets of normal healthy control patient cells from previously published studies were used: three Retroviral made iPSC (RV) and three Episomal made iPSC (EPI) (x100). Five F1 (n = 5) and three F2 (n = 3) cell populations was analyzed for proteomics between passage 3 to 9 (B) Table showing proteins characteristic of human mesenchymal stem cells (MSC), hematopoietic cells and fibroblasts that have either been identified or not in the F1 and F2 cells. The p-value indicates that there is no difference in the amount of these proteins between F1 and F2 indicating that the F1 and F2 cell types are similar. (C) Table showing the differential proteins between F1 and F2 involved in the immune response according to Reactome and Panther. (D) Table showing the differential proteins between F1 and F2 involved in signal transduction according to Reactome. (E) Schematic diagram of the main pathways overrepresented (in yellow) of all proteins detected (Reactome). (F) Interactions among the differential proteins involved in signal transduction and the TLR3, TLR4, IL6 and CCL2 proteins. (Highest confidence = minimum interaction score of 0.900) (G) Interactions among the differential proteins involved in immune system and the TLR3, TLR4, IL6 and CCL2 proteins. (Highest confidence = minimum interaction score of 0.900). (H) Validation of proteomic screen in three (n = 3) F1 and three F2 cell populations by flow cytometry for fibroblast markers CD90, CD44 and negative control marker CD34 (MSC marker) in F1 and F2 cells, demonstrating that the two populations of fibroblasts are similar. (I) Validation of proteomic screen in three (n = 3) F1 and three F2 cell populations by western blot for signal transduction proteins AKT Ser 478, total AKT and loading control Actin. Two from three matched pairs of cells demonstrated increased AKT signaling in F2 cells (EPI-2 the exception, see Fig. 4C).




**Figure 2. Characterization of adaptive and innate immune system in human iPSC. (A)** Genotype of the HLA of the six control healthy patient human fibroblasts (n = 6) previously reprogrammed into hiPSC in other published studies. RV: Retroviral made iPSC. EPI: Episomal made iPSC **(B)** Graph of the RT-PCR HLA gene expression levels (n = 6) in healthy control patient fibroblasts (F1), subsequent iPSC clones and iPSC-derived fibroblasts (F2) demonstrating no difference in HLA gene expression between F1 and F2 cells. **(C)** Flow cytometry histograms of the six patient iPSC derived fibroblasts (F2) (n = 6) for MHC-I protein expression in three Retroviral made iPSC (RV) and three Episomal made iPSC (EPI). **(D)** Graph representing expression levels of MHC-I (n = 3) by flow cytometry for F1 cells and F2 cells stimulated with 10 ng/ml INF-gamma overnight. **(E)** Table of RT-PCR analysis of TLR3 gene expression levels in F1 and F2 cells of pairs of cells (n = 10) demonstrating that the wild type human TLR3 gene is overexpressed between two and nine fold more cells in F2 iPSC-derived cells in eight from ten matched healthy cells (80%). **(F)** Representative flow cytometry histograms of F1 and F2 cells stained for TLR3 receptor expression confirming that wild type human TLR3 is overexpressed in two to five fold more cells in F2 cells for one retroviral made iPSC-made pair, one episomal made iPSC-made pair (for RV and EPI, F1 and F2 cells are fibroblasts) and one synthetic mRNA made iPSC-made pair (F1 are HFF cells and F2 are NSC). (n = 3).




**Figure 3. Human TLR3 isoform transcription start site is hypomethylated in human iPSC-derived cells and exclusively expressed in humans.** In addition to human iPSC used in Figures 1 and 2, a human fibroblast (HFF) cell line (Life Technologies) was reprogrammed by transfection of synthetic mRNA of the reprogramming factors to make six human iPSC lines and differentiated to NSC for further in depth analysis (characterization of mRNA made hiPSC in a separate publication) **(A)** Methylome array raw data for all Toll genes for F1 (HFF), six human iPSC and six F2 (NSC) cell lines. **(B)** Methylation profile of HFF (F1), iPSC and NSC (F2) demonstrating four CpGs that containing a transcription start site (TSS) in TLR3 is hypo-methylated in iPSC and NSC (F2 cells) but not in stating HFF (F1 cells). Methylation regions were considered significant using the following bioinformatic criteria: (i) more than 20% difference in CpG methylation levels between F1 and F2, (ii) more than one CpG island affected and (iii) at least 2 hiPSC or NSC clones affected, **(C)** Validation of hypomethylated TSS by pyrosequencing for two CpGs in human iPSC confirming the CpG TSS region of an isoform TLR3 is hypomethylated. **(D)** Sketch of bioinformatics of the TLR3 WT and TLR3 Isoform demonstrating the TSS site (red) associated with Acetylation (yellow) and DNase hypersensitivity sites (dark blue) that indicate gene expression on, and homology to other species (green). TLR3 isoform is uniquely expressed in humans and Rhesus Monkey. Lower panel: Detailed sketch of the exons of the shorter TLR3 isoform discovered from the methylome array, compared to wild type (WT) TLR3 for comparison. Brown and blue arrows show gene regions showing RT PCR primer sequences.



**Figure 4. Human TLR3 isoform is overexpressed in most human iPSC derived cells not seen in normal human tissue or cells (A)** Expression of the shorter human isoform TLR3 with unique 5' UTR in Red. Below the PCR of genomic DNA from human iPSC-derived neural stem cells (NSC) and cardiomyocytes (CM) of the unique 5' UTR of the TLR3 isoform. Sequencing data of the PCR product for the 5' UTR of the human TLR3 isoform (in Red) with whole sequence found at UC011CKZ.2 or XM\_017008577.1 transcript variant X1. Underlined regions are RT-PCR primer sequences used to detect human isoform TLR3. *Lower left panel:* Western blot of TLR3 expression demonstrating expression of the WT TLR3 at 107 KDa and the putative shorter TLR3 isoform at approximately 80 KDa in F1 cells (HFF) and F2 cells iPSC-derived NSC with schematic drawing of WT and Isoform human TLR3 missing the LRR1-8 region important in binding viral dsRNA and receptor stability **(B)** Table of individual F1 and F2 cell lines for RT-PCR analysis of gene expression demonstrating that the human TLR3 isoform gene is overexpressed between three to eighty-one fold more in F2 4 iPSC-derived cells in five from six matched healthy cells (83%). In red it is highlighted the exception healthy control patient sample (Epi-2) that also did not have elevated AKT signal transduction protein levels in F2 cells seen in Figure 1. **(C)** Graph comparing WT TLR3 (FL: Full Length) and isoform TLR3 gene expression in five normal healthy cells and tissues compared to synthetic mRNA made iPSC-derived cells (dotted line divides normal from iPSC cells analysed). Normal cells/tissues include: starting fibroblasts (HFF), normal endogenous bone marrow mesenchymal stem cells (BM MSC), cord blood umbilical stem cells (USCC), and normal tissues: normal hippocampus and frontal cortex human brain tissue demonstrating, demonstrating low levels of gene expression of the shorter TLR3 isoform in normal tissues. *Dotted line:* Compared to the synthetic mRNA made reprogrammed human iPSC differentiated into three different iPSC-derived cells: cardiomyocytes (CM), neural stem cells (NSC), endoderm (ENDO) and motor neurons (MN) demonstrating a significant increase in gene expression of the shorter TLR3 isoform in all types of iPSC-derived cell types tested. **(D)** Graph of an ELISA assay of the functional response of IL6 in human foreskin fibroblasts (F1, n = 2) and their mRNA made iPSC-derived neural stem cells (F2, n = 5) to LPS (100 ng/ml over 24 hours) and Poly (I:C) (1ug/ml) in triplicate, demonstrating a significantly suppressed IL6 immune response to Poly IC (1ug/ml over 24 hours) in iPSC-derived cells (F2 cells). *Note: Synthetic mRNA made iPSC and derived NSC, CM and DE have been characterized and described in another paper currently under consideration for publication.*



**Figure 5. Human TLR3 isoform functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC) (A)** Graph of RT-PCR for WT human TLR3 gene lentiviral overexpression in F2 cells (NSC that have high levels of expression of TLR3 isoform). Wild type (WT) human TLR3 lentivirus was used to overexpress WT TLR3 in five (n = 5) F2 (NSC) clones to functionally outcompete with the TLR3 isoform observed to be overexpressed in F2 cells **(B)**. Western blot analysis of phosphorylated p65 (p-p65) in two NSC (F2 cells) clones. Gain of function with WT TLR3 in F2 cells demonstrates the immune suppressive function of the short TLR3 isoform on TLR3 signal transduction in response to viral infection (Poly IC). After lentiviral overexpression of full length TLR3, NSC recover responsiveness to stimulation by the viral analog Poly (IC), as seen by the increase of phospho-p65 in the nuclear fraction. Control NSC were infected with a lentiviral empty vector (Ubiquitin promoter only (Ubc) that contained the same Ubiquitin promoter as the TLR3-LV vector. Loading controls are tubulin nuclear protein fraction. Representative pictures of five NSC tested. **(C)**. Schematic proposed model of full length TLR3 and the role of the shorter TLR3 isoform predominately expressed in reprogrammed cells that acts to suppress the immune response. All experiments performed with n = 6 at least twice, unless stated.



## Graphical abstract

**Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling:** Sustained wild type TLR3 and TLR3 isoform over expression is central to understanding the altered immunogenicity of human iPSC-derived cells calling for screening of human iPSC-derived cells for TLR3 expression levels before applications. **A.** Detailed sketch of the exons of the shorter TLR3 isoform discovered from the methylome array, compared to wild type (WT) TLR3 for comparison. **B.** Schematic proposed model of full length TLR3 and the role of the shorter TLR3 isoform predominately expressed in reprogrammed cells that acts to suppress the immune response.

